Xofigo+Xtandi beats Xtandi alone for ... - Advanced Prostate...

Advanced Prostate Cancer

22,372 members28,136 posts

Xofigo+Xtandi beats Xtandi alone for mCRPC

Tall_Allen profile image
31 Replies

Silke Gillessen presented the early results of PEACE3 at ESMO 2024. Compared to Xtandi alone, Xofigo+Xtandi:

• improved radiographic progression-free survival by 31%

• improved overall survival by 31%

These were men who had predominantly bone metastases and all received a bone strengthening agent (Zometa or Xgeva). They may have received Zytiga previously.

Written by
Tall_Allen profile image
Tall_Allen
To view profiles and participate in discussions please or .
Read more about...
31 Replies
Nickhmcg profile image
Nickhmcg

Unfortunately not the case for my Father, but mu goodness I hope it has helped so many others .

gsun profile image
gsun

That will be me someday. Thanks for the info! Do you have a link?

God_Loves_Me profile image
God_Loves_Me

Does that help to break hormone resistance ? I mean if I am planing to do Xofigo and Xtandi did not work in past in that case I can start Xtandi and start xofigo together and may see similar results base on clinical data ?

MoonRocket profile image
MoonRocket in reply toGod_Loves_Me

Probably not. This trial, at the basis, is about treating men with bone mets, hence the xofigo + Xtandi vs Xtandi alone. You'll need to consider BAT to to break hormone resistanc.

Tall_Allen profile image
Tall_Allen in reply toMoonRocket

BAT does not break hormone resistance. It may, in some cases, keep Xtandi working longer when it is given for mCRPC.

Tall_Allen profile image
Tall_Allen in reply toGod_Loves_Me

No. There is no known way to reverse castration resistance. I doubt it will work if Xofigo and Xtandi have already failed.

Tinuriel profile image
Tinuriel in reply toTall_Allen

This describes my husband's treatment regimen in the spring of '23. But Xtandi had already failed - still I wonder if continuing to take it while getting Xofigo is the reason his PSA remained somewhat stable during those months - not an expected result from Xofigo.

Howard53545 profile image
Howard53545

Based on PSMA I have a met on a rib bone and another spot. I have had spot radiation but I know the end is coming.

Tall_Allen profile image
Tall_Allen in reply toHoward53545

They accepted asymptomatic patients for the trial.

maley2711 profile image
maley2711 in reply toHoward53545

Yes, for all of us, PCa or not. I will note that there have bbeen numerous men here in your situation who have had very good prolongation of life with additional treatment.......perhaps you have already exhausted the options?

Icaneisawiwon75 profile image
Icaneisawiwon75

brilliant summary sir. Thank you

PresidentOfBelgium profile image
PresidentOfBelgium

Thanks for sharing 👍👍👍

GoBucks profile image
GoBucks

Is there also a similar trial with Xofigo + Zytiga?

Tall_Allen profile image
Tall_Allen in reply toGoBucks

The combination of Zytiga and Xofigo was tried in the ERA 223 trial. The trial was stopped early because there were about 3 times more fractures in the group receiving the combination than in the group receiving a placebo and Zytiga. The combination now carries a black-box warning against the combined use.

It appears that the problem may is resolved by using a bone-strengthening agent (like Xgeva or Zometa). When they looked at the subgroup who had taken bone-strengthening agents, 15% of those taking Xofigo+Zytiga vs 7% of those taking Zytiga-only experienced a fracture.

V10fanatic profile image
V10fanatic in reply toTall_Allen

Dropping from 3X down to 2X doesn't make me feel too warm and fuzzy. Also, since I've now exhausted my Xgeva treatment and only have one more Zometa infusion planned, it looks like I might need to consider switching over to Xtandi from my 5 year run of Zytiga(if that's even a viable option)

j-o-h-n profile image
j-o-h-n

Are you sure "It's Bone a fide?......

Good Luck, Good Health and Good Humor.

j-o-h-n

Tall_Allen profile image
Tall_Allen

As you know, I'm not a fan of youtube videos or podcasts. Even her presentation at ESMO is not ideal, although some conferences include a peer response. There's no need for a podcast among people not involved in the trial. It will be published in a peer-reviewed journal soon.

MateoBeach profile image
MateoBeach in reply toTall_Allen

Oh. Not published so we cannot review the study design, criteria, populations etc at this time? No way to evaluate what 31’% RPFS an 13% OS actually mean. Over what time period? Just the mean or more robust breakdown of distribution. I am skeptical of these limited conclusions That sound so conclusive. I expect you to be the advocate for careful analysis.

Tall_Allen profile image
Tall_Allen in reply toMateoBeach

Here's more details:

onclive.com/view/addition-o...

Details of the study design, criteria, populations, etc. are all given in the clinical trial design. This was a closely anticipated trial that came about after the problem of bone events stopped the trial of Xofigo+Zytiga. This trial was reviewed for interim results. The mortality of the control group was 80% so I don't expect it will change much upon publication.

MateoBeach profile image
MateoBeach in reply toTall_Allen

Thanks Allen. That is the info I wanted to review about it.

MoonRocket profile image
MoonRocket

Thanks Daryll. YouTube videos are just as good as non peer reviewed commentary websites. The reader or watcher can do their own home work.

BTW. The 2024 WSC will be 2 hours South on I-95 this year. Go Phillies!!!!

CAMPSOUPS profile image
CAMPSOUPS

It’s a hot button topic. One I normally coward in the corner from and hope everything turns out ok.

My wife became a different person a few years ago. I was often gone on work trips.

She fell deep into the rabbit hole algorithms of youtube.

She’s an intelligent person too.

It’s been said often but peer review is so important.

Unfortunately the New England Journal etc. doesn’t have enticing video’s for the average person and thus one of many draws to youtube.

Darryl profile image
DarrylPartner in reply toCAMPSOUPS

What I posted isn't a video. It's a ten minute audio recap for lay people about today's prostate cancer relevant presentations at ESMO.

CAMPSOUPS profile image
CAMPSOUPS in reply toDarryl

My apologies Darryl. I stand confused. As usual lol.

Tall_Allen profile image
Tall_Allen in reply toCAMPSOUPS

One of my problems with both youtube videos and podcasts is that I read so much faster than I can listen, even at 1.75X speed, which is about as fast as it can be to still be intelligible. Also, one K-M curve is worth a thousand words. For example, this transcript of an interview with Oliver Sartor about the SPLASH trial:

urotoday.com/video-lectures...

This has all the charts that nerds like me could want:

urotoday.com/conference-hig...

And this is a peer review:

urotoday.com/conference-hig...

CAMPSOUPS profile image
CAMPSOUPS in reply toTall_Allen

Wow yes. I'll have to try youtube videos at increased playback. Never thought of that but I doubt I'll be able to handle 1.75 lol.

Not to brag or I guess actually to brag ha. I have found myself at UroToday often over these last years.

Grateful for your nerdiness btw lol.

No_stone_unturned profile image
No_stone_unturned in reply toCAMPSOUPS

I agree there is a lot of B.S. out there that takes work to filter, but I'm never prepared to throw the baby out with the bath water. Sometimes youtube/podcasts are the only way to get new/novel info. Peer reviewed is important and it has a very important place in medical research and patient/dr decision processes, however it is also a group think network that only accepts things that potentially "qualifies" for funding. As a musician and recording artist, I can relate this to the music industry. It's less financially risky to sign/invest in or support a sound/style thats already popular. As a result, all new music sounds like old music and nothing truly innovative escapes the bubble. I fear, that the medical/pharma industry works similarly thus preventing new ideas from escaping the bubble. I for one feel fortunate that there are alternative venues to seek information as it can be a corrective tool for the profit driven model. Again, just be careful and don't believe everything you watch. Do your due diligence or stay away from the rabbit hole. my 2cents

Tall_Allen profile image
Tall_Allen in reply toNo_stone_unturned

I listen to a lot of music on youtube, but I know it is no place for medical science.

If one is willing to believe that there are medical scientific truths that make it to youtube that do not make it to peer-reviewed journals, one is already in that rabbit hole you warn against. What "due diligence" is possible if you are willing to believe any pseudoscience?

CAMPSOUPS profile image
CAMPSOUPS in reply toNo_stone_unturned

Sure yea.

Its my wife though. She doesn't have the filters you and I speak of.

But actually it doesnt matter too much in my personal case. I just watch youtube for car repair maintenance, hobbies (mini bikes etc.), and music. Prostate, cancer, etc. I get elsewhere.

My wife would be the person at the laptop in the cartoon.

I have the answers they missed
tarzantass profile image
tarzantass

Hi Tall Allen,

Will the combination of Xtandi and Xofigo be effective now that Xtandi alone is no longer effective to me? Does Xofigo best go with Xtandi but not with other anti-androgen drugs?

Thanks.

Tall_Allen profile image
Tall_Allen in reply totarzantass

That trial was among men who were Xtandi-naive. You may want to discuss using a different anti-androgen (i.e., apalutamide or darolutamide). Or, docetaxel has been shown to reverse enzalutamide resistance:

prostatecancer.news/2022/10...

And, the combination of Xofigo and docetaxel may work better than docetaxel alone, even with a reduced dose of docetaxel:

ejcancer.com/article/S0959-...

IMO, this would be a good time to add Provenge too:

ncbi.nlm.nih.gov/pmc/articl...

Not what you're looking for?

You may also like...

Sipuleucel-T boosts survival versus abiraterone or enzalutamide alone in real-world mCRPC analysis

The immunotherapy was also associated with fewer emergency department visits than either of the...
George71 profile image

Xtandi (enzalutamide) alone is superior to ADT alone at preventing metastases in "high-risk" recurrent men

"High-Risk"recurrence was defined as men who have had primary therapy (prostatectomy or radiation)...
Tall_Allen profile image

Xtandi with Xofigo??

There seems to be a discrepancy between oncs they both want me on Xofigo but one says I should...
sjpoli46 profile image

Xtandi+Keytruda may still work after Xtandi alone fails

In a small trial, 5 of 28 men (18%) got a PSA response (dropped at least by half) from the...
Tall_Allen profile image

MCRPC

I have a history of oligometastatic PCa since dx in 2013. See my profile. After relative quiescence...
Break60 profile image

Moderation team

Bethishere profile image
BethishereAdministrator
Number6 profile image
Number6Administrator
Darryl profile image
DarrylPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.